Resources>Antibody Industry Trends>Week 2, July 2024: An Update on Alzheimer’s Antibody Drugs

Week 2, July 2024: An Update on Alzheimer’s Antibody Drugs

Biointron 2024-07-09 Read time: 2 mins

The approval of Eli Lilly’s Kisunla (donanemab-azbt), a humanized IgG1 monoclonal antibody, is just one of the major advancements for the treatment of Alzheimer's disease (AD)! This drug is now available in the US for adults with early symptomatic AD, including those with mild cognitive impairment (MCI) and mild dementia stage of AD with amyloid pathology. Kisunla is the first and only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed, which can result in lower treatment costs and fewer infusions.

As the second treatment approved by the FDA that has been demonstrated to slow a decline in memory and thinking abilities, donanemab targets an epitope at the N-terminal of pyroglutamate Aβ (which is found only in the brain amyloid plaques associated with AD). It works by inducing microglial-mediated clearance of existing Aβ plaques with the intent of slowing the progressive decline in cognitive function associated with AD. 

anti-amyloid.png
Image credit: Alzheimer's Research UK

Other antibody drugs for AD that are currently in development or in clinical trials include: 

  • Aliada Therapeutics’ subcutaneous antibody, ALIA-1758, targets anti-pyroglutamate amyloid beta (3pE-Aβ), similar to the epitope targeted by donanemab. It uses a transferrin receptor to transport cargo to cells and force degradation and elimination of the plaques.  

  • Roche's bispecific antibody, trontinemab, is delivered by its Brainshuttle module, which also uses the transferrin receptor. It showed “best-in-class” potential based on its ability to quickly clear clumps of amyloid protein from the brains of patients in a small clinical trial. 

  • Eisai and Biogen have initiated a rolling Biologics License Application (BLA) for a weekly, subcutaneous version of Leqembi (lecanemab), the first monoclonal antibody medication approved by the FDA for treatment of AD last year. 

Meanwhile, in the research space, scientists from the NIH developed an innovative nasal spray treatment that has shown promising results in clearing harmful tau protein build-up and improving cognitive functions in aged mice models with neurodegenerative diseases. They developed a toxic tau conformation–specific monoclonal antibody-2 (TTCM2), which selectively recognized pathological tau aggregates in brain tissues from patients with AD, dementia with Lewy bodies (DLB), and progressive supranuclear palsy (PSP). This study could be valuable in designing effective tau immunotherapies for AD and other tauopathies.

Subscribe to our Antibody Industry Trends

Recommended Articles

Biointron Insights: Antibody Industry Report (Q1 2025 Insights, Trends & Analysis)

Biointron’s Q1 2025 annual antibody report aims to explore the events and trends……

Mar 31, 2025
Week 2, April 2025: Antibody-Targeted Therapies: A Look at FcRn Inhibitors and Fc Engineering

Just this week, Merida Biosciences emerged from stealth with a $121 million Seri……

Apr 08, 2025
April 2025: Affinity Maturation

Affinity maturation is a fundamental process in the adaptive immune response tha……

Apr 03, 2025
Week 1, April 2025: Emerging Trends in Fc Domain Engineering for Therapeutic Development

The therapeutic potential of monoclonal antibodies (mAbs) has expanded dramatica……

Apr 01, 2025

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.